tiprankstipranks
Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
US Market
RAPP
Rapport Therapeutics, Inc.
RESEARCH TOOLSreports

Rapport Therapeutics, Inc. (RAPP) Stock News & Sentiment

143 Followers
Advancing RAP-219: Phase 3 Progress, 2026 Catalysts, and Strategic China Partnership Support a Buy Rating
Premium
Ratings
Advancing RAP-219: Phase 3 Progress, 2026 Catalysts, and Strategic China Partnership Support a Buy Rating
1M ago
RAPP
Rapport Therapeutics Completes Key Phase 2a Epilepsy Study for RAP-219: What Investors Should Watch Next
Premium
Company Announcements
Rapport Therapeutics Completes Key Phase 2a Epilepsy Study for RAP-219: What Investors Should Watch Next
2M ago
RAPP
Rapport Therapeutics: Accelerated RAP-219 Epilepsy Path to Phase 3 and Strategic Pipeline Refocus Support Buy Rating
Premium
Ratings
Rapport Therapeutics: Accelerated RAP-219 Epilepsy Path to Phase 3 and Strategic Pipeline Refocus Support Buy Rating
3M ago
RAPP
Rapport Therapeutics: Diversified Neurology Pipeline and Accelerated RAP-219 Development Underpin Buy Rating
Premium
Ratings
Rapport Therapeutics: Diversified Neurology Pipeline and Accelerated RAP-219 Development Underpin Buy Rating
3M ago
RAPP
Premium
Ratings
Buy Rating on RAP-219 Underscored by Differentiated Clinical Profile, Conservative Phase 3 Design, and Favorable Risk–Reward
3M ago
RAPP
Premium
Company Announcements
Rapport Therapeutics Establishes $110 Million At-The-Market Offering
3M ago
8K
RAPP
Premium
Company Announcements
Rapport Therapeutics advances RAP-219 into Phase 3 epilepsy
3M ago
8K
RAPP
More RAPP News >

RAPP News on the Web

Insider Sell: Krishnaswamy Yeleswaram Sells Shares of Rapport Therapeutics Inc (RAPP)
GuruFocus News
Neutral
Closing Bell Movers: Markets on edge ahead of US-Iran talks
TipRanks News
Bullish
Rapport Therapeutics initiated with a Strong Buy at Raymond James
TipRanks News
Neutral
Insider Sell: Cheryl Gault Sells 10,000 Shares of Rapport Therapeutics Inc (RAPP)
GuruFocus News
Neutral
Insider Sell: Krishnaswamy Yeleswaram Sells Shares of Rapport Therapeutics Inc (RAPP)
GuruFocus News
Bearish
All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy
Zacks
Bullish
Analysts Offer Insights on Healthcare Companies: Immutep Ltd (OtherPRRUF), Coya Therapeutics, Inc. (COYA) and Rapport Therapeutics, Inc. (RAPP)
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), SAB Biotherapeutics (SABS) and Encompass Health (EHC)
TipRanks News
Bullish

News Score - Last 7 Days

Positive
RAPP
Sector Average
Media Buzz
This Week4 articles
Weekly Average2 articles
News Sentiment
This Week100%
Sector Average67%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is RAPP’s Media Buzz Sentiment?
4 articles about RAPP were published this week. In an average week, 2 articles are published.
    What is RAPP’s weekly average amount of articles?
    In an average week, 2 articles about RAPP are published.
      What is RAPP’s News Sentiment?
      100% of articles about RAPP were positive this week, compared to its sector average of 67%.
        Healthcare Stocks that are Trending in the News
        TXTMProText Mobility
        STAAStaar Surgical
        ALLOAllogene Therapeutics
        REPLReplimune Group
        IVVDInvivyd
        Showing the stocks with the most bullish news sentiment over the past week